Literature DB >> 19858500

Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome.

Oliver Rivero-Arias1, Melissa Ouellet, Alastair Gray, Jane Wolstenholme, Peter M Rothwell, Ramon Luengo-Fernandez.   

Abstract

BACKGROUND: Mapping disease-specific instruments into generic health outcomes or utility values is an expanding field of interest in health economics. This article constructs an algorithm to translate the modified Rankin scale (mRS) into EQ-5D utility values.
METHODS: mRS and EQ-5D information was derived from stroke or transient ischemic attack (TIA) patients identified as part of the Oxford Vascular study (OXVASC). Ordinary least squares (OLS) regression was used to predict UK EQ-5D tariffs from mRS scores. An alternative method, using multinomial logistic regression with a Monte Carlo simulation approach (MLogit) to predict responses to each EQ-5D question, was also explored. The performance of the models was compared according to the magnitude of their predicted-to-actual mean EQ-5D tariff difference, their mean absolute and mean squared errors (MAE and MSE), and associated 95% confidence intervals (CIs). Out-of-sample validation was carried out in a subset of coronary disease and peripheral vascular disease (PVD) patients also identified as part of OXVASC but not used in the original estimation.
RESULTS: The OLS and MLogit yielded similar MAE and MSE in the internal and external validation data sets. Both approaches also underestimated the uncertainty around the actual mean EQ-5D tariff producing tighter 95% CIs in both data sets.
CONCLUSIONS: The choice of algorithm will be dependent on the study aim. Individuals outside the United Kingdom may find it more useful to use the multinomial results, which can be used with different country-specific tariff valuations. However, these algorithms should not replace prospective collection of utility data.

Entities:  

Mesh:

Year:  2009        PMID: 19858500     DOI: 10.1177/0272989X09349961

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  46 in total

Review 1.  Evaluation of content on EQ-5D as compared to disease-specific utility measures.

Authors:  Fang-Ju Lin; Louise Longworth; A Simon Pickard
Journal:  Qual Life Res       Date:  2012-06-23       Impact factor: 4.147

2.  Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.

Authors:  Eun-ju Kim; Su-Kyoung Ko; Hye-Young Kang
Journal:  Qual Life Res       Date:  2011-10-20       Impact factor: 4.147

3.  Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.

Authors:  Mónica Hernández Alava; Allan Wailoo; Stephen Pudney; Laura Gray; Andrea Manca
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

4.  Stroke Treatment Academic Industry Roundtable Recommendations for Individual Data Pooling Analyses in Stroke.

Authors:  Kennedy R Lees; Pooja Khatri
Journal:  Stroke       Date:  2016-07-12       Impact factor: 7.914

5.  Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.

Authors:  Jason Madan; Kamran A Khan; Stavros Petrou; Sarah E Lamb
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

Review 6.  Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials.

Authors:  Joseph P Broderick; Opeolu Adeoye; Jordan Elm
Journal:  Stroke       Date:  2017-06-16       Impact factor: 7.914

7.  Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.

Authors:  Abdullah Pandor; Daniel Horner; Sarah Davis; Steve Goodacre; John W Stevens; Mark Clowes; Beverley J Hunt; Tim Nokes; Jonathan Keenan; Kerstin de Wit
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

8.  Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation.

Authors:  Jean-Eric Tarride; Lisa Dolovich; Gordon Blackhouse; Jason Robert Guertin; Natasha Burke; Veena Manja; Alex Grinvalds; Ting Lim; Jeff S Healey; Roopinder K Sandhu
Journal:  CMAJ Open       Date:  2017-08-22

9.  Pipeline embolization device versus coiling for the treatment of large and giant unruptured intracranial aneurysms: a cost-effectiveness analysis.

Authors:  Arvin R Wali; Charlie C Park; David R Santiago-Dieppa; Florin Vaida; James D Murphy; Alexander A Khalessi
Journal:  Neurosurg Focus       Date:  2017-06       Impact factor: 4.047

10.  Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices.

Authors:  Jeffrey L Saver; Tudor G Jovin; Wade S Smith; Gregory W Albers; Jean-Claude Baron; Johannes Boltze; Joseph P Broderick; Lisa A Davis; Andrew M Demchuk; Salvatore DeSena; Jens Fiehler; Philip B Gorelick; Werner Hacke; Bill Holt; Reza Jahan; Hui Jing; Pooja Khatri; Chelsea S Kidwell; Kennedy R Lees; Michael H Lev; David S Liebeskind; Marie Luby; Patrick Lyden; J Thomas Megerian; J Mocco; Keith W Muir; Howard A Rowley; Richard M Ruedy; Sean I Savitz; Vitas J Sipelis; Samuel K Shimp; Lawrence R Wechsler; Max Wintermark; Ona Wu; Dileep R Yavagal; Albert J Yoo
Journal:  Stroke       Date:  2013-11-05       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.